Based in India’s southern state of Tamil Nadu, Parry Nutraceuticals received the U.S. Food and Drug Administration approval for its India facility for organic micro-algae cultivation and processing.
Business head, Parry Nutraceuticals, Muthu Murugappan said that some of the products that they planned to bring to market over the next two years include Organic Chlorella, Spirulina Granules, CO2 Extracted Lutein and Algal Beta Glucan. New areas currently under development include vegan algal proteins, chlorophyll and algae omega-3s, reports Outlook.
Valensa International, based in Florida, which specializes in the development of condition-specific nutraceuticals such as joint, eye and cardio-vascular health issues, is a wholly owned subsidiary of Parry.
